BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Atezolizumab: trial readouts and FDA decisions
5 upcoming industry Phase 2/3 readout(s) in the next 90 days, 0 upcoming FDA event(s), 6 readout(s) in the last 180 days and 0 FDA event(s) in the last 12 months. Sponsors: Hoffmann-La Roche, Genentech, Inc., Nanjing Leads Biolabs Co.,Ltd, AbbVie, Biotheus Inc., Kahr Bio Australia Pty Ltd, Exelixis. Drug names come from ClinicalTrials.gov intervention names and FDA records, lightly normalised; one drug can appear under several names (code, generic, brand).
Upcoming trial readouts
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-11-30 est. | P3 | Hoffmann-La Roche | NCT03148418 A Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A) | Cancer | active not recruiting | 382 |
| 2026-11-30 est. | P2 | Genentech, Inc. | NCT04302025 A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC) | Non-small Cell Lung Cancer | active not recruiting | 99 |
| 2026-12-28 est. | P1/P2 | Nanjing Leads Biolabs Co.,Ltd | NCT06157827 A Clinical Trial of LBL-024 Combined With Etoposide and Platinum in Patients With Advanced Neuroendocrine Carcinoma | Advanced Neuroendocrine Carcinoma | recruiting | 178 |
| 2026-12-31 est. | P2 | Hoffmann-La Roche | NCT05645692 A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Met | Urothelial Cancer | active not recruiting | 204 |
| 2027-01 est. | P2/P3 | AbbVie ABBV | NCT06109272 A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as a | Hepatocellular Carcinoma | active not recruiting | 89 |
Readouts, last 180 days
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-10-22 | P1/P2 | Hoffmann-La Roche | NCT03533283 An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma | Non-Hodgkins Lymphoma | completed | 211 |
| 2026-10-14 est. | P3 | Hoffmann-La Roche | NCT04770896 A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and B | Unresectable Hepatocellular Carcinoma | active not recruiting | 557 |
| 2026-10 est. | P1/P2 | Biotheus Inc. | NCT06584071 A Study to Evaluate of PM8002 Combined With PM1009 in Patients With First-line HCC | HCC; Liver Cancer | not yet recruiting | 140 |
| 2026-09-30 est. | P2 | Kahr Bio Australia Pty Ltd | NCT07235293 A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorectal Cancer. | Colorectal Cancer | recruiting | 90 |
| 2026-07-22 | P3 | Hoffmann-La Roche | NCT04543617 A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Follo | Esophageal Squamous Cell Carcinoma | completed | 760 |
| 2026-06-16 | P3 | Exelixis EXEL | NCT05425940 Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal Cancer | Colorectal Cancer | active not recruiting | 901 |
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.